Littérature scientifique sur le sujet « CREBBP »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « CREBBP ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "CREBBP"
1
Yu, Chuanjiang, Mara Holloman, Andrew Kim, et al. "Differential Role of Crebbp Missense and Truncating Mutations in the Malignant Transformation of Germinal Center B Cells." Blood 144, Supplement 1 (2024): 47. https://doi.org/10.1182/blood-2024-208876.
Texte intégralRésumé :
Somatic mutations of the CREBBP acetyltransferase are highly recurrent in germinal center (GC)-derived lymphomas, including follicular lymphoma (FL, 60% of cases) and diffuse large B cell lymphoma (DLBCL; 40% of cases in the EZB/C3 genetic subtype). Mutations include prototypical inactivating events that abrogate the C-terminal acetyltransferase (AT) domain, as well as amino-acid changes clustering within this domain, which impair the protein enzymatic activity by decreasing its affinity for acetyl-coenzyme A (Pasqualucci et al., Nature 2011). These events are acquired early during lymphomagenesis, in a putative common precursor cell (CPC) that subsequently undergoes divergent evolution to FL or tFL through the acquisition of additional genetic lesions. While extensive work has focused on understanding the lymphoma-driving role of CREBBP protein loss, mimicking the outcome of truncating mutations, the functional significance of missense mutations remains largely unexplored. This is a critical gap because, different from truncated proteins, CREBBP missense mutants are expressed, suggesting they may contribute to malignant transformation through distinct mechanisms. In support of this view, missense and truncating mutations are differentially distributed in FL and DLBCL, with the former being preferentially enriched in FL (p<0.01). The aim of this study was to investigate the in vivo role of CREBBP missense mutations during the initial phases of lymphomagenesis, and contrast it with the phenotype resulting from CREBBP loss. To address these questions, we took advantage of a novel, conditional knock-in mouse model where the most common R1446H mutant protein (R1447 in mice, hereafter CrebbpRH) is expressed specifically in GC B cells under the control of its endogenous promoter, following T cell-dependent immunization and Cγ1Cre-driven recombination. RT-PCR and sequencing confirmed efficient, GC-restricted activation of the knock-in allele, and Crebbp protein levels were comparable in homozygous CrebbpRH vs WT littermates, documenting a stable protein. While modest differences were noted in the GC B cell fraction of CrebbpKO mice, consistent with our previous work, expression of the CrebbpRH allele led to pronounced, dose-dependent expansion of the GC (p<0.001), the structure from which FL and DLBCL arise. These GCs displayed an abnormal dark zone to light zone polarity manifesting as an increased proportion of centrocytes (p<0.001), and persisted abnormally for several weeks after immunization, when the GC reaction is normally extinguished, indicating an altered dynamics. To investigate the mechanisms underlying this phenotype, we contrasted the transcriptomic and chromatin profiles of CrebbpRH and CrebbpKO GC B cells. We found shared but also unique transcriptional changes separating the two cohorts by unsupervised hierarchical clustering. Consistently, a significant number of differentially expressed genes were unique to CrebbpRH vs CrebbpKO GC B cells (q<0.05, FC≥1.2). In particular, CrebbpRH GCs were positively enriched in light-zone-associated and pre-memory B cell differentiation programs (Ccr6, Gpr183, Klf2); in contrast, these signatures were attenuated upon Crebbp deletion, indicating missense mutations may favor distinct cell fates upon GC exit. While global H3K27Ac was reduced in both CrebbpRH and CrebbpKO cells, consistent with impaired AT activity, Cut&Run analysis revealed a significant CrebbpRH-mediated redistribution of the H3K27Ac mark at super-enhancers, including those linked to genes involved in GC exit and B:T-cell interactions. Accordingly, expression of CrebbpRH alleles led to a two-fold increase in memory B cell responses to the T cell-specific antigen NP-KLH (p<0.01), which was not detected in CrebbpKO mice, as measured by immunophenotyping. Moreover, CrebbpRH but not CrebbpKO mice showed compositional changes in the T cell microenvironment, with expansion of T follicular helper cells (8.3%, vs 3.8% in WT mice; p<0.05). Thus, Crebbp missense mutations may skew GC B cell fate decisions toward memory B cell differentiation and favor the persistence of enlarged GCs to facilitate the malignant transformation process, in part by shaping the GC microenvironment. These data have implications for the understanding of FL/DLBCL ontogeny and for the therapeutic targeting of tumors carrying missense vs truncating mutations.
2
Meyer, Stefanie, Sofija Vlasevska, Laura Garcia Ibanez, Claudio Scuoppo, Riccardo Dalla-Favera, and Laura Pasqualucci. "Targeting Histone Acetyltransferase Gene Inactivation in Diffuse Large B Cell Lymphoma." Blood 132, Supplement 1 (2018): 671. http://dx.doi.org/10.1182/blood-2018-99-117542.
Texte intégralRésumé :
Abstract Diffuse Large B-cell Lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma, accounting for ~30% of de-novo diagnoses and also arising as a frequent clinical evolution of indolent lymphomas. Although curable in a substantial fraction of cases, one third of patients do not achieve durable remissions, highlighting the need for novel, targeted therapies. Over the past decade, we and others have identified the CREBBP acetyltransferase and, less frequently, its paralogue EP300 as highly recurrent targets of inactivating somatic mutations/deletions in DLBCL and follicular lymphoma (FL) (30% and 60% of patients, respectively), indicating a prominent role in the pathogenesis of these tumors (Pasqualucci et al., Nature 2011). In most cases, mutations are heterozygous and the residual wildtype (WT) allele is expressed, suggesting a haploinsufficient tumor suppressor role. Indeed, germinal center (GC)-specific loss of Crebbp perturbs the expression of genes that are relevant to the normal biology of this structure, i.e. the lymphoma cell of origin, and cooperates with BCL2 deregulation to increase the incidence of tumors recapitulating the features of the human disease (Zhang et al., Cancer Discovery 2017). Intringuingly, while CREBBP binds to virtually all GC-specific superenhancers, no detrimental effects were observed upon its deletion in mice, suggesting the existence of compensatory mechanisms. Consistent with this hypothesis, inactivation of CREBBP and EP300 rarely coexist in human DLBCL and FL, suggesting that cells require a certain amount of acetyltransferase activity. To investigate whether EP300 compensates for CREBBP loss in the GC, we analyzed the GC responses in compound mouse models engineered to specifically delete these two genes (alone and in combination) upon SRBC immunization and induction of a Cγ1-driven Cre-recombinase. While CrebbpKOmice showed a mild increase in GC formation, as reported, loss of Ep300 led to ~40% reduction in the percentage of GC cells (mean: 1.8% vs 3.1% in WT littermates; p<0.05), documenting that these two enzymes play non-entirely overlapping roles in this population. Importantly, GC formation was completely abrogated in CrebbpKOEp300KO mice and dramatically impaired in CrebbpHETEp300KO mice, as compared to both WT and single EP300KO mice. These data suggest that GC B cells require a minimum amount of acetyltransferase activity, and reveal a potential therapeutically exploitable dependency of Crebbp-mutated GC B cells on Ep300. In order to probe if a similar dependency exists in neoplastic GC B cells, we used an inducible CRISPR/Cas9 system to delete EP300 (or a control non-genic region) in 4 DLBCL cell lines representative of the various CREBBP genotypes found in DLBCL, and monitored cell proliferation and survival in competition assays over 12 days. Compared to CREBBPWT, CREBBP heterozygous and homozygous mutant cells were significantly counter-selected from the total population following doxycycline induced EP300 deletion (~30% at day 7). Moreover, no EP300-edited clones were recovered from the CREBBP mutant lines in single cell plating assays, compared to CREBBP WT (p<0.01). Thus, DLBCL cells remain addicted to the residual EP300 aceyltransferase activity, supporting the existence of a therapeutic window for EP300 inhibitors. To explore this concept further, we generated isogenic DLBCL clones carrying WT or defective CREBBP alleles (n=4 each), and performed drug-sensitivity assays with 2 novel small molecule inhibitors that specifically target the CREBBP/EP300 HAT or BRD domain. While, at higher doses, both inhibitors interfered with cell growth in all clones, CREBBPKO cells were significantly more sensitive than their isogenic WT pairsat low nanomolar ranges (IC50: 60nM vs 300nM). Importantly, we were able to design an in vitro protocol that was toxic to CREBBPKO cells but tolerated by CREBBPWT cells, providing a proof of concept for therapeutically targeting these molecules. In conclusion, we show that CREBBP and EP300 have differential roles in normal GC B cell development and that CREBBP mutated cells are addicted to the residual EP300 activity. This dependency is maintained in DLBCL cells, providing the basis for the potential application of acetyl transferase inhibition into the clinical settings. Disclosures No relevant conflicts of interest to declare.
3
Ying, Hsia-Yuan, Yanwen Jiang, Ana Ortega-Molina, et al. "Crebbp Mutations Disrupt Dynamic Enhancer Acetylation in B-Cells, Enabling HDAC3 to Drive Lymphomagenesis." Blood 128, no. 22 (2016): 735. http://dx.doi.org/10.1182/blood.v128.22.735.735.
Texte intégralRésumé :
Abstract Somatic mutations in CREBBP occur frequently in germinal center derived lymphomas such as DLBCL and FL. However whether or how these mutations might contribute to lymphomagenesis is still largely unknown. Most CREBBP mutations are predicted to result in loss of function since they target the histone acetyltransferase (HAT) domain or give rise to premature stop codon prior to the HAT domain. Here, we show that Crebbp shRNA knockdown (KD) accelerated lymphomagenesis in VavP-Bcl2 transgenic mice, a model that recapitulates human GC-derived lymphomas. The median time to lymphoma onset in VavP-Bcl2/CrebbpKD mice was 114 days, significantly shorter than control VavP-Bcl2/GFP mice (193 days, p=0.04). Histopathology revealed that VavP-Bcl2/CrebbpKD lymphomas were more aggressive and widely disseminated than VavP-Bcl2/GFP lymphomas. CREBBP can regulate gene enhancer function through H3K27 acetylation. ChIP-seq in VavP-Bcl2/CrebbpKD lymphoma cells revealed significant reduction of H3K27ac peaks compared to control lymphoma cells (N = 1717, Kolmogorov-Smirnov test, p<2.2E-16). Loss of H3K27ac was markedly skewed towards enhancers. We observed similar loss of enhancer H3K27ac in human DLBCL cells after CREBBP shRNA KD. Enhancer H3K27ac loss was significantly associated with repression of nearby genes in both murine (FDR q=0.044) and human lymphoma cells (FDR q=0). RNA-seq performed in three independent FL or DLBCL patient cohorts revealed a characteristic CREBBP mutant gene expression signature featuring prominent transcriptional repression (p=1.32E-14, p=0.001, and p=0.0002 respectively). Notably, the human patient CREBBP mutant signature was highly enriched in murine and human cell line CREBBP shRNA profiles (FDR=0, GSEA), indicating that CREBBP KD signature was highly similar to CREBBP mutant signature in humans. Functional analysis of the CREBBP mutant/KD signature showed significant enrichment of GC exit pathways including genes induced by CD40, IRF4 and plasma cell differentiation; as well as immune response processes including antigen processing and presentation, such as MHC class II genes (BH-adjusted p<0.05). To better understand mechanism we performed an integrative analysis of CREBBP signatures against databases of B-cell transcription factor and epigenome profiles. This analysis yielded significant enrichment (BH-adjusted p<0.05) for i) enhancers bound by the BCL6 transcriptional repressor and its SMRT/HDAC3 corepressor complex, ii) enhancers that are normally deacetylated in GC B-cells, and iii) genes induced by BCL6 siRNA. This is notable because in normal GCs BCL6 represses enhancers by recruiting SMRT/HDAC3 complexes to deacetylate H3K27. Hence our data suggest that CREBBP is a counteracting HAT to BCL6/SMRT/HDAC3. Indeed, conditional knockout of Hdac3 in GC B-cells in mice resulted in impaired GC formation and a transcriptional signature featuring upregulation of the same genes that are repressed by CREBBP KD (GSEA FDR=0). Moreover, CREBBP KD in DLBCL cells resulted in H3K27ac loss at BCL6/SMRT/HDAC3 regulated enhancers, including those nearby CDKN1A, NFATC1, FOXP1, and MHC II genes, such as HLA-DQA1 and HLA-DRB5. CREBBP KD also resulted in silencing of these genes. Since we show HDAC3 is the opposing HDAC to CREBBP then we reasoned that CREBBP mutant DLBCLs might be especially dependent on HDAC3. Indeed we observed that HDAC3 shRNA resulted in profound suppression of CREBBP mutant DLBCL cells in vitro and in vivo (DLBCL xenografts in mice, p=0.005), whereas CREBBP WT cell lines were barely affected by HDAC3 KD. The opposing effects of BCL6/SMRT/HDAC3 and CREBBP on MHC class II could have implications for immune surveillance. Accordingly CREBBP KD induced significant loss of cell surface HLA-DR molecules (p<0.05), and these cells exhibited up to 90% less capability to stimulate T-cell response in allogeneic mixed lymphocyte reaction experiments. The loss of MHC class II molecules and T-cell response was rescued when CREBBP loss of function cells were exposed to a specific HDAC3 inhibitor. In summary, CREBBP mutations drive lymphomagenesis by enabling unopposed suppression of enhancers by BCL6/SMRT/HDAC3 complexes, resulting in a repressive transcriptional programming that disrupts GC exit and evades immune surveillance. HDAC3 targeted therapy may rescue these effects and serve as a precision approach for CREBBP mutant lymphomas. Disclosures Scott: Celgene: Consultancy; Roche: Honoraria; Janssen: Consultancy; BC Cancer Agency: Patents & Royalties: Inventor on a patent licensed to NanoString Technologies. Tam:Millennium Pharmaceuticals, Inc.: Consultancy. Melnick:Janssen: Research Funding.
4
LeBlanc, Francis, Josh Bennett, Kwangmin Choi, and Daniel T. Starczynowski. "Targeting CREB-Binding Protein (CREBBP) Overcomes Resistance to Azacitidine and Venetoclax Therapy in Acute Myeloid Leukemia (AML)." Blood 142, Supplement 1 (2023): 5765. http://dx.doi.org/10.1182/blood-2023-187063.
Texte intégralRésumé :
Acute myeloid leukemia (AML) is a clonal myeloid malignancy arising from hematopoietic stem or progenitor cells (HSPC) within the bone marrow (BM). Despite advancements in our understanding of AML pathogenesis, patients continue to face grim outcomes, with a five-year relative survival rate of approximately 20%. This highlights the pressing need to identify molecular features of AML that are amenable to therapeutic intervention. The ideal molecular targets would be those broadly dysregulated and integral to multiple signaling pathways implicated in AML pathogenesis. Recent therapeutic regimens have incorporated venetoclax, a small molecule inhibitor of BCL2, in combination with hypomethylating agents, showing moderate success. Venetoclax (VEN) acts as a BH3 mimetic, specifically inhibiting BCL2. While clinical outcomes of VEN combined with hypomethylating agents (decitabine or azacitidine - AZA) have been promising, a substantial subset of patients remains refractory or experiences relapse following treatment with these regimens. Due to the molecular and cellular heterogeneity of AML, identifying ideal mechanisms to circumvent resistance remains elusive. In our investigations, we have observed that patient-derived cells from AML exhibit a higher frequency of dysregulated immune and inflammatory pathways than previously appreciated, referred to as “oncogenic immune signaling states.” Furthermore, immune and inflammatory-related pathways are preferentially expressed in AML patients who are resistant/refractory to VEN/AZA compared to those who respond favorably. To identify critical immune and inflammatory-related pathways contributing to VEN/AZA responses, we developed an oncogenic immune signaling-targeted CRISPR-library, aimed at identifying potential therapeutic targets involved in VEN/AZA resistance in AML. Utilizing this targeted CRISPR-screen approach, we successfully identified CREB-binding protein (CREBBP) as the top candidate linked to resistance to VEN/AZA therapy. Notably, CREBBP alterations have been associated with a poor prognosis in de novo AML, making it a compelling target for further investigation. To validate CREBBP's role in VEN/AZA resistance, we treated a VEN/AZA-resistant AML cell line, THP1 (FAB subtype M5, KMT2A-r), with commercially available pharmacologic inhibitors of CREBBP, A485, and CCS1477, and assessed the response. Remarkably, inhibition of CREBBP with either A485 or CCS1477 significantly decreased cell proliferative ability and clonogenic potential. Importantly, co-treatment with either A485 or CCS1477 and VEN/AZA synergistically abrogated cell proliferation and clonogenic potential of THP1 cells, effectively overcoming resistance (Figure 1). Our ongoing studies include validating CREBBP as a potential therapeutic target for overcoming VEN/AZA resistance in AML. We have created CREBBP-knockdown cell lines through genetic manipulation (shRNA) and will utilize these to confirm the specificity of CREBBP in modifying resistance to VEN/AZA. In addition we will utilize patient-derived xenograft studies in immunocompromised (NRG) mouse models. By investigating CREBBP's role in mediating resistance, we aim to unlock new avenues for enhancing the efficacy of VEN/AZA therapy in AML patients, particularly those facing resistance to current therapies. In conclusion, our research highlights the critical involvement of CREBBP in VEN/AZA resistance in AML. Targeting this molecular pathway holds the promise of offering a potential therapeutic approach to improve treatment outcomes for AML patients, particularly those facing resistance to current therapies. Understanding and harnessing CREBBP's influence could pave the way for developing personalized and effective strategies to combat this challenging hematological malignancy.
5
Lamble, Adam J., Robert B. Gerbing, Jenny L. Smith, et al. "Crebbp Alterations Are Associated with a Poor Prognosis in De Novo AML." Blood 138, Supplement 1 (2021): 3451. http://dx.doi.org/10.1182/blood-2021-154052.
Texte intégralRésumé :
Abstract Introduction: The translocation, t(8;16)(p11;p13), results in the fusion between KAT6A and CREBBP and has been associated with a poor prognosis in both pediatric and adult acute myeloid leukemia (AML). This lesion has therefore been re-classified as high risk on the active Phase 3 Children's Oncology Group (COG) trial for de novo AML, AAML1831 (NCT04293562). Less is known about the prognostic significance of CREBBP sequence variants. Methods: CREBBP variant status was determined in patients with AML enrolled on 4 successive COG trials for de novo pediatric AML (NCT00003790, NCT00070174, NCT01407757, NCT01371981). Fusions involving CREBBP were prospectively obtained via conventional cytogenetics and retrospectively confirmed via RNAseq. Insertions and deletions (indels) leading to frameshift mutations and single nucleotide variants (SNVs) were retrospectively interrogated via next generation sequencing. Results: Of 2216 patients (age: 0-29.8 years), 55 (2.5%) patients had an alteration involving CREBBP. Sixteen (29%) of these were a fusion involving CREBBP (CREBBP/fus), with KAT6A being the most common translocation partner (n=15) and the remaining translocation involving ANK1. The remaining 39 patients (71%) had a CREBBP mutation (CREBBP/mut), including 19 with an indel (CREBBP/indel) leading to a frameshift mutation and 20 with a SNV (CREBBP/SNV). We compared clinical and biologic characteristics between the three cohorts. CREBBP/fus patients were significantly younger than CREBBP/indel and CREBBP/SNV patients (median ages of 2.6 vs. 7.8 vs. 11.9 years; p=0.027). There was a higher prevalence of t(8;21)/RUNX1-RUNX1T1 in CREBBP/indel patients compared to CREBBP/SNV patients (42.1% vs. 5%; p=0.008). In contrast, CREBBP/SNV patients were more likely to be associated with a normal karyotype (40% vs. 5.3%; p=0.02). There was a similar prevalence of co-occurring high-risk lesions in CREBBP/indel (n=5; CBFA2T3-GLIS2, KMT2A-AFF1, KMT2A-MLLT4, MLLT10-PICALM, NUP98-HOXA9) and CREBBP/SNV (n=7; DEK-NUP214, ETV6-FOXO1, FUS-ERG, NUP98-NSD1, ETV6-MNX1, FLT3-ITDx2) patients. There was otherwise no difference between presenting WBC count, FLT3-ITD, NPM1, CEBPA, remission rates or MRD status after Induction 1 therapy. Patients with any CREBBP alteration had a significantly worse 5-year event free survival (EFS) compared to patients without (25.9% vs. 45.2%; p=0.002) and this inferior EFS overlaps with contemporarily defined high-risk patients (Figure 1a). Evaluation of outcomes based on type of alteration demonstrated a similar 5-year EFS of 33.3% and 23.1% between CREBBP/fus and CREBBP/mut patients, respectively (Figure 1b; p=0.832). This poor EFS was maintained in the CREBBP/indel patients with a co-occurring t(8;21) (n=8, 5-year EFS 12.5%). When patients with co-occurring high-risk lesions were excluded from analysis, the remaining CREBBP/mut (n=27) patients maintained their poor EFS (29.6%). Despite their poor EFS, CREBBP/mut patients had an analogous overall survival (OS) to non-CREBBP patients (57.4% vs. 62.3%; p=0.499, Figure 1c), demonstrating that these patients could be successfully salvaged following relapse. In contrast, all patients with CREBBP/fus that relapsed subsequently died from their disease (OS 33.3%). Conclusions: In a large study of CREBBP alterations in pediatric patients with de novo AML, we show that these patients have a dismal EFS, regardless of alteration type. Further, despite enrichment of t(8;21), the favorable prognosis typically conferred by this alteration was abrogated by the co-occurrence of CREBBP/indel. Similarly, by excluding patients with co-occurring high-risk lesions from analysis, we show that these poor outcomes persist in a cohort of patients that would otherwise be considered low risk. Translocations between CREBBP and KAT6A in patients over 90 days of age are considered high risk on the active COG phase 3 trial. Given the inferior EFS and high salvage rates associated with other CREBBP alterations, intensification of upfront treatment, including hematopoietic stem cell transplant, should be considered in this population. The authors would like to acknowledge Astellas Pharma Global Development, Inc. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.
6
Zhu, Yu, Zi Wang, Yanan Li, et al. "The Role of CREBBP/EP300 and Its Therapeutic Implications in Hematological Malignancies." Cancers 15, no. 4 (2023): 1219. http://dx.doi.org/10.3390/cancers15041219.
Texte intégralRésumé :
Disordered histone acetylation has emerged as a key mechanism in promoting hematological malignancies. CREB-binding protein (CREBBP) and E1A-binding protein P300 (EP300) are two key acetyltransferases and transcriptional cofactors that regulate gene expression by regulating the acetylation levels of histone proteins and non-histone proteins. CREBBP/EP300 dysregulation and CREBBP/EP300-containing complexes are critical for the initiation, progression, and chemoresistance of hematological malignancies. CREBBP/EP300 also participate in tumor immune responses by regulating the differentiation and function of multiple immune cells. Currently, CREBBP/EP300 are attractive targets for drug development and are increasingly used as favorable tools in preclinical studies of hematological malignancies. In this review, we summarize the role of CREBBP/EP300 in normal hematopoiesis and highlight the pathogenic mechanisms of CREBBP/EP300 in hematological malignancies. Moreover, the research basis and potential future therapeutic implications of related inhibitors were also discussed from several aspects. This review represents an in-depth insight into the physiological and pathological significance of CREBBP/EP300 in hematology.
7
Hashwah, Hind, Corina A. Schmid, Sabrina Kasser, et al. "Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth." Proceedings of the National Academy of Sciences 114, no. 36 (2017): 9701–6. http://dx.doi.org/10.1073/pnas.1619555114.
Texte intégralRésumé :
The genes encoding the histone acetyl-transferases (HATs) CREB binding protein (CREBBP) and EP300 are recurrently mutated in the activated B cell-like and germinal center (GC) B cell-like subtypes of diffuse large B cell lymphoma (DLBCL). Here, we introduced a patient mutation into a human DLBCL cell line using CRISPR and deleted Crebbp and Ep300 in the GC B cell compartment of mice. CREBBP-mutant DLBCL clones exhibited reduced histone H3 acetylation, expressed significantly less MHCII, and grew faster than wild-type clones in s.c. and orthotopic xenograft models. Mice lacking Crebbp in GC B cells exhibited hyperproliferation of their GC compartment upon immunization, had reduced MHCII surface expression on GC cells, and developed accelerated MYC-driven lymphomas. Ep300 inactivation reproduced some, but not all, consequences of Crebbp inactivation. MHCII deficiency phenocopied the effects of CREBBP loss in spontaneous and serial transplantation models of MYC-driven lymphomagenesis, supporting the idea that the mutational inactivation of CREBBP promotes immune evasion. Indeed, the depletion of CD4+ T cells greatly facilitated the engraftment of lymphoma cells in serial transplantation models. In summary, we provide evidence that both HATs are bona fide tumor suppressors that control MHCII expression and promote tumor immune control; mutational inactivation of CREBBP, but not of EP300, has additional cell-intrinsic engraftment and growth-promoting effects.
8
Zimmer, Stephanie N., Qing Zhou, Ting Zhou, et al. "Crebbp haploinsufficiency in mice alters the bone marrow microenvironment, leading to loss of stem cells and excessive myelopoiesis." Blood 118, no. 1 (2011): 69–79. http://dx.doi.org/10.1182/blood-2010-09-307942.
Texte intégralRésumé :
Abstract CREB-binding protein (CREBBP) is important for the cell-autonomous regulation of hematopoiesis, including the stem cell compartment. In the present study, we show that CREBBP plays an equally pivotal role in microenvironment-mediated regulation of hematopoiesis. We found that the BM microenvironment of Crebbp+/− mice was unable to properly maintain the immature stem cell and progenitor cell pools. Instead, it stimulates myeloid differentiation, which progresses into a myeloproliferation phenotype. Alterations in the BM microenvironment resulting from haploinsufficiency of Crebbp included a marked decrease in trabecular bone that was predominantly caused by increased osteoclastogenesis. Although CFU-fibroblast (CFU-F) and total osteoblast numbers were decreased, the bone formation rate was similar to that found in wild-type mice. At the molecular level, we found that the known hematopoietic modulators matrix metallopeptidase-9 (MMP9) and kit ligand (KITL) were decreased with heterozygous levels of Crebbp. Lastly, potentially important regulatory proteins, endothelial cell adhesion molecule 1 (ESAM1) and cadherin 5 (CDH5), were increased on Crebbp+/− endothelial cells. Our findings reveal that a full dose of Crebbp is essential in the BM microenvironment to maintain proper hematopoiesis and to prevent excessive myeloproliferation.
9
Huntly, Brian J. P., Sarah Jayne Horton, George Giotopoulos, et al. "Early Loss of CREBBP Confers Malignant Stem Cell Properties on Lymphoid Progenitors." Blood 128, no. 22 (2016): 460. http://dx.doi.org/10.1182/blood.v128.22.460.460.
Texte intégralRésumé :
Abstract Loss-of-function mutations of the cyclic-AMP response element binding protein, binding protein (CREBBP) gene have recently been described at high frequencies across a spectrum of lymphoid malignancies, particularly follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). The multiple effects of this epigenetic regulator on developmental and homeostatic processes have been extensively studied, however, exactly how CREBBP functions as a tumor suppressor and the reasons for its particular predilection for suppression of lymphoid tumors remains unclear. In addition, for many mature lymphoid malignancies, the existence of cancer stem cells is unproven and their provenance and the initial target cell for transformation a source of ongoing debate. Here we use multiple mouse strains to model loss of Crebbp in different lymphoid compartments to address these questions. We demonstrate that early loss of Crebbp in hematopoietic stem and progenitor cells (HSPC), through disruption by the Mx1-Cre recombinase, leads to increased development of hematological malignancies, particularly of the B-lymphoid lineage that mimic features of human lymphomas. Theses B-cell malignancies are of long latency and are preceded by significant alterations in the proliferation, self-renewal and differentiation of lymphoid progenitors, allowing hyperproliferative lymphoid progenitors whose differentiation is blocked to accumulate. Using an aberrant surface phenotype that resembles the eventual tumor, we identify a pre-malignant population in the peripheral blood of animals that is often evident many months before any disease characteristics. We demonstrate pre-malignant stem cell characteristics for this population in functional experiments, where it generates high level reconstitution of peripheral blood in transplant recipients, but only gives rise to disease in these animals after a long latency. We also utilize this unique cellular population in longitudinal genome scale analyses (clonality, RNA-Seq, ChIP-Seq and exome sequencing) to document the mechanisms of malignant evolution. Linking the increased rate of mutation we describe to Crebbp loss, we also demonstrate increased DNA damage and an altered DNA-damage response in premalignant lymphoid progenitors. Importantly, using a Cd19-Cre recombinase that excises only within committed lymphoid cells, we are able to demonstrate that when Crebbp is lost at a later stage of lymphoid development, the marked cellular abnormalities described above are completely lost and the development of tumors is no different from normal (Figure, below). Taken together, these findings define the developmental stage-specific tumor suppressor functions of Crebbp and shed light on the cellular origins and subsequent evolution of lymphoid malignancies. In addition, the altered response to DNA damage that we demonstrate upon loss of Crebbp, allied to the increased exposure to physiological DNA-damage during lymphoid ontogeny offers an explanation for the high incidence of CREBBP mutations in mature lymphoid malignancies. Figure Left panel, Kaplan Meier graph for Mx1-Cre Crebbp mice with loss of Crebbp in the HSPC compartment demonstrates significantly shorter survival vs WT littermates with intact expression of Crebbp. In contrast, when Crebbp is excised in a later lymphoid compartment through Cd19-Cre mediated recombination, right panel, no difference in survival is noted from WT littermate controls. Figure. Left panel, Kaplan Meier graph for Mx1-Cre Crebbp mice with loss of Crebbp in the HSPC compartment demonstrates significantly shorter survival vs WT littermates with intact expression of Crebbp. In contrast, when Crebbp is excised in a later lymphoid compartment through Cd19-Cre mediated recombination, right panel, no difference in survival is noted from WT littermate controls. Disclosures Huntly: Novartis: Speakers Bureau; BMS: Speakers Bureau; Ariad: Speakers Bureau; Pfizer: Speakers Bureau.
10
Peck, Barrie, Philip Bland, Ionnana Mavrommati, et al. "3D functional genomics screens identify CREBBP as a targetable driver in aggressive triple-negative breast cancer." Cancer Res 81, no. 4 (2021): 847–59. https://doi.org/10.1158/0008-5472.CAN-20-1822.
Texte intégralRésumé :
Triple-negative breast cancers (TNBC) are resistant to standard-of-care chemotherapy and lack known targetable driver gene alterations. Identification of novel drivers could aid the discovery of new treatment strategies for this hard-to-treat patient population, yet studies using high-throughput and accurate models to define the functions of driver genes in TNBC to date have been limited. Here, we employed unbiased functional genomics screening of the 200 most frequently mutated genes in breast cancer, using spheroid cultures to model <em>in vivo</em>–like conditions, and identified the histone acetyltransferase CREBBP as a novel tumor suppressor in TNBC. CREBBP protein expression in patient tumor samples was absent in 8% of TNBCs and at a high frequency in other tumors, including squamous lung cancer, where CREBBP-inactivating mutations are common. In TNBC, CREBBP alterations were associated with higher genomic heterogeneity and poorer patient survival and resulted in upregulation and dependency on a FOXM1 proliferative program. Targeting FOXM1-driven proliferation indirectly with clinical CDK4/6 inhibitors (CDK4/6i) selectively impaired growth in spheroids, cell line xenografts, and patient-derived models from multiple tumor types with CREBBP mutations or loss of protein expression. In conclusion, we have identified CREBBP as a novel driver in aggressive TNBC and identified an associated genetic vulnerability in tumor cells with alterations in CREBBP and provide a preclinical rationale for assessing CREBBP alterations as a biomarker of CDK4/6i response in a new patient population. <strong>Significance:</strong> This study demonstrates that CREBBP genomic alterations drive aggressive TNBC, lung cancer, and lymphomas and may be selectively treated with clinical CDK4/6 inhibitors.
Thèses sur le sujet "CREBBP"
1
Dixon, Zach Adam. "The role of CREBBP mutations in lymphoid malignancies." Thesis, University of Newcastle upon Tyne, 2016. http://hdl.handle.net/10443/3556.
Texte intégralRésumé :
Relapsed acute lymphoblastic leukaemia (ALL), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) comprise a group of malignancies with poor prognosis and therapeutic strategies are needed to improve outcomes. Recent studies have shown that heterozygous inactivating mutations in the histone acetyl transferase, CREBBP, are frequent in these malignancies, and are thought to lead to impaired transcription of glucocorticoid (GC) response genes. Given the pivotal role of GC in the treatment of lymphoid malignancies and the finding that CREBBP mutations often arise at relapse, it has been postulated that CREBBP mutations confer chemoresistance to GC therapy. To study the role of CREBBP haploinsufficiency in ALL, DLBCL and FL, small hairpin RNA and small interfering RNA methods were used to knock down CREBBP in a number of cell lines and primary derived samples. Models were functionally relevant, with reduced acetylation of CREBBP target residue, histone 3 lysine 18 and/or histone 3 lysine 27, but knockdown had no significant impact on activation of cAMP-dependent target genes. Impaired induction of glucocorticoid receptor targets was only seen in 1 of 4 CREBBP knockdown models of ALL, and there was no significant difference in GC-induced apoptosis or chemosensitivity to other therapeutic agents frequently used in lymphoid malignancies, including histone deacetylase inhibitors. However, CREBBP knockdown was associated with enhanced signalling of the RAS/RAF/MEK/ERK pathway in RAS pathway mutant ALL cells, and MEK inhibitor sensitivity was retained. This suggests that CREBBP mutation may act to enhance the activity of oncogenes and that CREBBP/RAS pathway mutated relapsed ALL are candidates for MEK inhibitor clinical trials.
2
Dawes, Joanna Camilla. "Modelling Crebbp loss in BCL2 driven non-Hodgkin's lymphoma." Thesis, Imperial College London, 2015. http://hdl.handle.net/10044/1/58194.
Texte intégralRésumé :
Non-Hodgkin’s lymphomas (NHL) are a spectrum of hematopoietic cancer accounting for 4% of new cancer diagnoses each year. Approximately 95% of all NHL are of B-cell origin; diffuse large B-cell lymphomas (DLBCL) and follicular lymphoma (FL) accounting for 30-40% and 20% of B-NHL respectively. Recent human mutation profiling and resequencing studies have shown that CREBBP and BCL2 are frequently mutated, early events in B-NHL that are often are concurrent. This thesis presents a study of their role in oncogenesis by generating a novel model of B-NHL overexpressing BCL2 in the haematopoetic compartment combined with the conditional heterozygous loss of Crebbp in the germinal centre B-cells. Loss of Crebbp significantly accelerated BCL2 driven lymphomagenesis. Characterisation of these lymphomas by flow cytometry demonstrated that they were phenotypically similar to mature human B-cell lymphomas of germinal centre origin. Additionally an insertional mutagenesis screen was performed in mice sensitised to B-NHL. Somatic MoMuLV caused mutations interact with the sensitising mutations, facilitating tumourigenesis and recapitulating the stepwise and accumulative progression of human disease. Provirus insertions were detected using a novel method of insertion site cloning called UMI-LM-PCR which amplifies the region flanking the provirus. Insertions were then mapped to the mouse genome flagging genes with a putative role in tumourigenesis. This method represents the highest throughput method to date and its applicability to Illumina sequencing permits the most comprehensive quantitative survey of subclonal mutations. This work confirms Crebbp is a tumour suppressor gene and that its loss cooperates with overexpression of BCL2 to accelerate lymphomagenesis. Through insertional mutagenesis screening of this model hundreds of putative cancer genes have been identified including Pou2f2 and Tfrc which have a propensity for mutation specifically in B-cell lymphomas deficient in Crebbp and overexpressing BCL2. These candidates now need to be validated to better characterise their role in B-cell lymphoma.
3
BENTIVEGNA, ANGELA. "Ricerca di alterazioni del Gene CREBBP (CREB Binding Protein) in pazienti con sindrome di Rubinstein-Taybi." Bachelor's thesis, Università degli Studi di Milano-Bicocca, 2004. http://hdl.handle.net/10281/12824.
Texte intégral
4
Di, Dio Laura Giusy Rosaria Agata. "Sindrome da microduplicazione 16p13.3 espansione del fenotipo." Doctoral thesis, Università di Catania, 2012. http://hdl.handle.net/10761/1062.
Texte intégralRésumé :
Le sindromi da microalterazione cromosomica sono sindromi costituzionali con ritardo mentale e anomalie fenotipiche multiple causate da sbilanci di specifiche regioni del genoma. Se il riarrangiamento cromosomico include poche megabasi viene detto criptico perché spesso non è diagnosticabile con un esame cromosomico convenzionale.
Per molti anni, tuttavia, cioè fino a quando è stata disponibile solo la tecnica tradizionale e FISH per l analisi di cromosomi metafasici, erano conosciute soltanto le microdelezioni delle regioni fiancheggiate da dupliconi. La mancata diagnosi citogenetica-molecolare delle microduplicazioni è stata attribuita a vari possibili fattori: ad un evento selettivo di microdelezione mediato dai dupliconi,
ad una mancata penetranza clinica della duplicazione, che, essendo in genere meglio tollerata sul piano fenotipico rispetto alla delezione, può sfuggire all accertamento clinico.
In realtà l applicazione della tecnica array-CGH nella diagnosi del ritardo mentale idiopatico, sta dimostrando come le stesse regioni interessate da microdelezione siano spesso interessate da microduplicazione, con possibile fenotipo clinico, confermando che il meccanismo di ricombinazione omologa non allelica è un frequente e specifico meccanismo di mutazione cromosomica strutturale.
Nel genoma sono presenti CNV (copy number variation) o polimorfismi (delezioni, duplicazioni, amplificazioni) che hanno diverse dimensioni da 40kb a 2Mb e sono ampiamente distribuiti in tutto il genoma. Vista l ampia distribuzione di CNV lo studio del DNA parentale aiuta l interpretazione dei dati forniti dagli array-CGH.
Un ulteriore tipologia della tecnica di array-CGH è quella definita SNP array (Single Nucleotide Polymorphism). Questa metodologia sfrutta l elevato polimorfismo di genomi individuali relativi a singoli nucleotidi. La tecnica SNP array è in grado di diagnosticare non solo variazioni quantitative del genoma ma anche le disomie uniparentali, l origine parentale di uno sbilancio.
Riportiamo un caso con caratteristiche fenotipiche riconoscibili, ritardo psicomotorio e di crescita, in cui è stata rilevata dagli SNP-array una duplicazione di 0.4 Mb nella regione cromosomica 16p13.3. Tale regione è implicata nella sindrome di Rubinstein Taybi, dovuta a microdelezione della regione o delezione del gene CREBBP o mutazione del gene CREBBP con loss of function.
5
BENTIVEGNA, ANGELA. "Base molecolare della sindrome di Chromatin remodelling Rubinstein-Taybi: un sistema modello per lo studio dei deficit funzionali di acetilazione istonica." Doctoral thesis, Università degli studi di Milano, 2008. http://hdl.handle.net/10281/12823.
Texte intégralRésumé :
Rubinstein–Taybi syndrome (RSTS) is a rare malformation disorder caused by mutations in the closely related CREBBP and EP300 genes, accounting respectively for up to 60 and 3% of cases. About 10% of CREBBP mutations are whole gene deletions often extending into flanking regions. Using FISH and microsatellite analyses as a first step in the CREBBP mutation screening of 63 Italian RSTS patients (pts), 6 deletions were identified, 3 of which were in a mosaic condition that has not been previously reported in RSTS. The clinical presentation was typical in all cases, but more severe in the three pts carrying constitutional deletions, raising a question about the possible underdiagnosis of a few cases of mild RSTS. The use of region-specific BAC clones and small CREBBP probes allowed to assess the extent of all of the deletions by mapping their endpoints to genomic intervals of 5–10 kb. Four of five intragenic breakpoints cluster at the 5' end of CREBBP, where there is a peak of breakpoints underlying rearrangements in RSTS pts and tumours. The search for genomic motifs did not reveal any low-copy repeats (LCRs) or any greater density of repetitive sequences. The FISH analysis extended to the EP300 genomic region did not reveal any deletions. Searching for mutations of CREBBP gene in 56 patients revealed 23 different mutations. In addition, one deletion and two amplifications were identified by a-CGH in 20 RSTS pts.
6
Camós, Guijosa Mireia. "Caracterización biológica de la leucemia mieloide aguda con translocación t(8;16)(p11;p13) y reordenamiento MYST3-CREBBP." Doctoral thesis, Universitat de Barcelona, 2007. http://hdl.handle.net/10803/2220.
Texte intégralRésumé :
INTRODUCCIÓN. La leucemia mieloide aguda (LMA) es una enfermedad heterogénea desde el punto de vista clínico y biológico. En los últimos años se vienen reconociendo diversas alteraciones moleculares que definen entidades específicas. En este contexto, la LMA con translocación t(8;16)(p11;p13) y reordenamiento MYST3 (MOZ)/CREBBP (CBP) es una variedad infrecuente mal caracterizada desde el punto de vista biológico. <br/><br/>HIPÓTESIS Y OBJETIVOS. La proteína quimérica MYST3-CREBBP, resultante de la translocación t(8;16)(p11;p13), podría conferir a este subtipo de LMA una individualidad biológica propia, con rasgos diferenciados respecto al resto de leucemias. Para confirmar esta hipótesis general los objetivos de la presente tesis doctoral fueron: 1) diseñar una técnica de PCR para el diagnóstico rápido y específico del reordenamiento MYST3-CREBBP; 2) caracterizar el punto de ruptura de los genes implicados en la translocación en una serie de pacientes y 3) estudiar el perfil de expresión génica de las LMA con reordenamiento MYST3-CREBBP y compararlo con el de otros subtipos bien definidos de LMA.<br/><br/>PACIENTES Y MÉTODOS. Se estudió una serie de pacientes con LMA y reordenamiento MYST3-CREBBP (n=7) y se compararon sus características biológicas con otros casos de LMA. Para ello se diseñó una técnica de PCR nueva para la detección del reordenamiento MYST3-CREBBP, mientras que los puntos de ruptura de los genes implicados en la translocación se estudiaron mediante secuenciación directa. El estudio del perfil de expresión génica de la LMA con reordenamiento MYST3-CREBBP se abordó utilizando microarrays de oligonucleótidos (Affymetrix HU133A). La diferencia entre la expresión génica entre diferentes subtipos de leucemia se analizó con diversas técnicas estadísticas (ANOVA, t-test), utilizando diferentes programas informáticos. Los resultados de este análisis se validaron en una serie independiente de pacientes estudiados mediante RT-PCR cuantitativa utilizando arrays de baja densidad. <br/><br/>RESULTADOS. Los pacientes afectos de LMA con reordenamiento MYST3-CREBBP presentaron un inmunofenotipo característico (CD34-, HLA-DR-, CD117-, CD56+, expresión de marcadores mielomonocíticos). Por otro lado, el análisis molecular reveló que el tránscrito tipo I del gen quimérico MYST3-CREBBP es el más común en estos pacientes. Por otra parte, el análisis sobre el perfil de expresión génica mostró una firma característica para las LMA con reordenamiento MYST3-CREBBP, consistente en la sobreexpresión de determinados genes HOX (HOXA9, HOXA10), de los oncogenes RET y PRL y la infraexpresión de genes como CCND2, STAT5 y WT1. Por otro lado, se observó una similitud en la expresión de algunos genes entre las leucemias MYST3-CREBBP y las LMA con reordenamiento de MLL, lo que sugiere un mecanismo de leucemogénesis parcialmente compartido por los dos tipos de leucemia.<br/><br/>CONCLUSIONES. La técnica de RT-PCR implementada es útil para la detección rápida del reordenamiento MYST3-CREBBP. El denominado tránscrito tipo I del gen quimérico MYST3-CREBBP es el más común en la LMA con t(8;16). La LMA con reordenamiento MYST3-CREBBP posee un perfil de expresión característico, con sobreexpresión de diversos oncogenes como RET y PRL y la presencia de un patrón específico de expresión de los genes homeobox.
7
Torres, Leuridan Cavalcante. "Avaliação da imunocompetência de portadores da síndrome de Rubinstein-taybi." Universidade de São Paulo, 2008. http://www.teses.usp.br/teses/disponiveis/42/42133/tde-01092008-192345/.
Texte intégralRésumé :
A síndrome de Rubinstein-Taybi (RTS, OMIM 180849) é uma doença autossômica dominante caracterizada por dismorfismos craniofaciais típicos, polegares e háluces alargados, infecções respiratórias recidivantes, retardo mental e de crescimento. RTS está associada com mutação no gene CREBBP. Na avaliação da imunocompetência de 17 portadores de RTS, observaram-se algumas alterações na resposta imune inata e adaptativa: leucocitose persistente, neutrófilos com desgranulopoiese, elevada concentração sérica de IgM e IgG1, produção normal de anticorpos contra antígenos protéicos e anti-polissacarídeos, elevados valores absolutos de células B totais, B \"naive\", B de memória, subpopulação B1 e de linfócitos B com IgM de membrana, e elevado percentual de apoptose de linfócitos B. DTH negativo para três antígenos e baixa resposta linfoproliferativa para antígenos protéicos. Diante do exposto, concluímos que os pacientes RTS apresentam alterações em vários mecanismos da resposta imune e principalmente, na imunidade humoral. Portanto, com este trabalho foi possível identificar as principais alterações imunológicas destes pacientes, e com isso, caracterizar quais os defeitos da resposta imune que pode estar associada com gene CREBBP.<br>Rubinstein-Taybi syndrome (RTS, OMIM 180849) is a dominant Mendelian disorder characterized by craniofacial dysmorphisms, broad thumbs and toes, mental retardation and growth and recurrent respiratory infections. RTS is classically associated with CREBBP gene mutations, but recently, p300 gene mutations were reported in three individuals. In imunonocompetence investigation of a group of 17 patient of the RTS, we found that the patients really show alterations in more than one arm of the immune response. The main alterations were found in: a) innate immunity, patients have defects in the distribution of the granules citoplasmatic and partial absence of F-actin filament part of its polymorphonuclear cells. In addition, some patients had decreased phagocytic activity, b) humoral immunity: elevated serum IgM antibodies and IgG1 subclass, normal production of antibodies for protein antigens and antipolysaccharide, high absolute values of B cell total, B \"naive\", B memory, subpopulation B1 and B lymphocytes with the membrane IgM, and high percentage of apoptosis of B lymphocytes; c) cellular immunity: delayed hypersensitivity skin tests negative for three antigens and low lymphoproliferative response to protein antigens. Values reduced percentage of CD45RA+ , CD45RO+ T cells and high doublepositive CD45RA+/CD45RO +) T cell. Ahead of the severe recurrent respiratory infections that affect the patients with RTS, and of the evaluation of immunocompetence of these patients, we find that they have several alterations in mechanisms of immune response and mainly in humoral immunity. Therefore, with this study was to identify the major immunological alterations of these patients, and with this, which characterize the main defects of the immune response of the patients RTS that can is associated with gene CREBBP.
8
Djavanroodi, Faramarz. "Creep and creep-fracture crack growth." Thesis, Imperial College London, 1989. http://hdl.handle.net/10044/1/47412.
Texte intégral
9
Whitt, Harrison Collin. "Creep and Creep-fatigue Deformation Studies in 22V and P91 Creep-strength EnhancedFerritic Steels." The Ohio State University, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=osu1555603135480185.
Texte intégral
10
Giannopoulos, Ioannis. "Creep and creep-rupture behaviour of Aramid fibres." Thesis, University of Cambridge, 2010. https://www.repository.cam.ac.uk/handle/1810/252181.
Texte intégralRésumé :
To obtain creep-rupture data at low level within a reasonably short time-scale, two accelerated techniques have been investigated. Stepped Isothermal Method (SIM) testing involves loading a single specimen, under constant load, with the temperature increased in a series of steps to accelerate the creep. Careful choice of the temperature step and step duration allow the test to be completed in about 24 hours. At each temperature step a creep curve is obtained; these are then adjusted to compensate for the different temperature levels and a creep master curve at a reference temperature is produced. In Stepped Isostress Method (SSM) testing, a similar approach is adopted but the acceleration is obtained by increasing the stress in steps while keeping the temperature constant. Additional stress provides energy to the system in an analogue of the effect of heat in SIM. In this thesis, SIM and SSM tests have been successfully applied to two slightly different aramid fibres, Kevlar 49 and Technora, for a wide range of loads (50-80% ABL). The test data are used to determine the creep and creep-rupture behaviour of the two materials. The creep master curves obtained by accelerated testing are compared with conventional creep tests at ambient conditions, and good agreement of the data is observed. A rheological model for the prediction of the creep and creep-rupture of the two fibres is established to facilitate and greatly increase the reliability of the prediction of the long-term behaviour. This investigation allows more certainty about the creep-rupture relationships for different high modulus fibres, which will in turn allow more realistic safety factors to be applied when using these materials in engineering applications.
Livres sur le sujet "CREBBP"
2
de, Villiers H. L., ed. The physics of creep: Creep and creep-resistant alloys. Taylor & Francis, 1995.
Trouver le texte intégral
3
Betten, Josef. Creep Mechanics. Springer Berlin Heidelberg, 2002. http://dx.doi.org/10.1007/978-3-662-04971-6.
Texte intégral
5
service), SpringerLink (Online, ed. Creep Mechanics. Springer-Verlag Berlin Heidelberg, 2008.
Trouver le texte intégralChapitres de livres sur le sujet "CREBBP"
1
Hall, Christine M., Amaka C. Offiah, Francesca Forzano, Mario Lituania, Gen Nishimura, and Valérie Cormier-Daire. "Rubinstein-Taybi Syndrome, CREBBP- and EP300-Related." In Fetal and Perinatal Skeletal Dysplasias, 2nd ed. CRC Press, 2024. http://dx.doi.org/10.1201/9781003166948-61.
Texte intégral
2
Razdolsky, Leo. "Peculiarities of Phenomenological Models of Nanocomposites." In Creep. CRC Press, 2023. http://dx.doi.org/10.1201/9781003267720-4.
Texte intégral
3
Razdolsky, Leo. "Phenomenological Creep-Fatigue Models." In Creep. CRC Press, 2023. http://dx.doi.org/10.1201/9781003267720-3.
Texte intégral
4
Razdolsky, Leo. "Cumulative Damage Model (CDM) of Cyclic Creep-Fatigue Process." In Creep. CRC Press, 2023. http://dx.doi.org/10.1201/9781003267720-2.
Texte intégral
5
Razdolsky, Leo. "Probabilistic Approach to Creep-Fatigue Models." In Creep. CRC Press, 2023. http://dx.doi.org/10.1201/9781003267720-5.
Texte intégral
6
Razdolsky, Leo. "Introduction and Assumptions." In Creep. CRC Press, 2023. http://dx.doi.org/10.1201/9781003267720-1.
Texte intégral
7
Sandström, Rolf. "Creep with Low Stress Exponents." In Basic Modeling and Theory of Creep of Metallic Materials. Springer Nature Switzerland, 2024. http://dx.doi.org/10.1007/978-3-031-49507-6_5.
Texte intégralRésumé :
AbstractPrimary creep models predict that at low stresses a stress exponent of 1 can be obtained for dislocation creep. Also experimentally this has been observed for an austenitic stainless steel. The time dependence of the primary creep verifies that it is dislocation creep. An other example is for Al at very high temperatures (Harper-Dorn creep), where at sufficiently low stresses, the stress exponent approaches 1. For both materials higher stresses give larger stress exponents as expected for dislocation creep. Obviously, diffusion and dislocation creep can be competing processes. The validity of creep models at low stresses and high temperatures as well as at high stresses and low temperatures demonstrates their wide range of usage. Since this in reality represents an extensive extrapolation, it can be consider as a direct verification of the basic creep models. In cases for Cu and stainless steels, the predicted creep rate by diffusion creep (Coble) exceeds the observed creep rate as well as the predicted one by dislocation creep by an order of magnitude. The likely explanation is that constrained boundary creep is taken place, i.e. the grain boundary creep rate cannot be essentially faster than that of the bulk.
8
Sandström, Rolf. "Primary Creep." In Basic Modeling and Theory of Creep of Metallic Materials. Springer Nature Switzerland, 2024. http://dx.doi.org/10.1007/978-3-031-49507-6_4.
Texte intégralRésumé :
AbstractFor many materials, primary creep can be described with the phi (ϕ) model and tertiary creep with the Omega (Ω) model (discussed in Chap. 12). According to the phi model, the creep rate is linear in strain and time in a double logarithmic diagram. When using empirical descriptions of the creep curves, these models are recommended. Several basic models for primary creep are derived. They are based on the creep rate in the secondary stage. This means that primary creep can be derived without any new data. The primary creep models are in agreement with the phi model and can describe experimental data. For the martensitic 9–12% Cr steels at least two dislocation densities are needed to represent primary creep because the initial dislocation density is high contrary to the situation for annealed fcc materials.
9
John, Vernon. "Creep and Creep Testing." In Testing of Materials. Macmillan Education UK, 1992. http://dx.doi.org/10.1007/978-1-349-21969-8_7.
Texte intégral
10
Migoń, Piotr. "Creep." In Encyclopedia of Natural Hazards. Springer Netherlands, 2013. http://dx.doi.org/10.1007/978-1-4020-4399-4_79.
Texte intégralActes de conférences sur le sujet "CREBBP"
1
Green, Michael R. "Abstract IA25: CREBBP: Not all mutations are created equal." In Abstracts: AACR Virtual Meeting: Advances in Malignant Lymphoma; August 17-19, 2020. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/2643-3249.lymphoma20-ia25.
Texte intégral
2
"Анализ молекулярных последовательностей гена CREBBP методом главных компонент (PCA-seq)". У Биоинформатика регуляции и структуры геномов / системная биология. ИЦиГ СО РАН, 2024. http://dx.doi.org/10.18699/bgrs2024-9.1-06.
Texte intégral
3
Chang, Yunchao, David W. Woessner, Wenwei Lin, et al. "Abstract IA12: Modeling and targeting CREBBP mutations in relapsed acute lymphoblastic leukemia." In Abstracts: AACR Special Conference: Pediatric Cancer Research: From Basic Science to the Clinic; December 3-6, 2017; Atlanta, Georgia. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.pedca17-ia12.
Texte intégral
4
Zhou, Ting, Ziming Cheng, Christi Walter, and Vivienne I. Rebel. "Abstract B27: Novel insights into the pathogenesis of myelodysplastic syndrome using Crebbp+/- mice." In Abstracts: AACR Special Conference: Pediatric Cancer at the Crossroads: Translating Discovery into Improved Outcomes; November 3-6, 2013; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.pedcan-b27.
Texte intégral
5
Pickering, Curtis, Manish Kumar, Kathleen Bridges, et al. "Abstract 2925: Targeting histone acetyltransferase (HAT) function for synthetic cytotoxicity in CREBBP/EP300 mutant tumors." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-2925.
Texte intégral
6
Pickering, Curtis, Manish Kumar, Kathleen Bridges, et al. "Abstract 2925: Targeting histone acetyltransferase (HAT) function for synthetic cytotoxicity in CREBBP/EP300 mutant tumors." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-2925.
Texte intégral
7
Peck, Barrie, Philip J. Bland, Patty T. Wai, et al. "Abstract 788: Modeling tumor microenvironmental heterogeneity identifies CREBBP as a novel tumor suppressor in breast cancer." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-788.
Texte intégral
8
Li, Jiaping, Wenzhe Fan, Yue Zhao, et al. "Abstract 2236: A Pan-cancer Analysis of CREBBP as a potential predictor for immune checkpoint therapy." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-2236.
Texte intégral
9
Natrajan, Rachael. "Abstract P3-10-17: CREBBP alterations lead to CDK4/6 inhibitor sensitivity in triple negative breast cancer." In Abstracts: 2019 San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, Texas. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.sabcs19-p3-10-17.
Texte intégral
10
Kumar, Manish, Kathleen Bridges, David Molkentine, et al. "Abstract 978: In vivo shRNA screening identifies synthetic cytotoxicity in CREBBP/EP300 mutant head and neck cancer." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-978.
Texte intégralRapports d'organisations sur le sujet "CREBBP"
1
Brenkus, Natassia, Garrett Tatum, Pedram Ghassemi, and Lautaro Martinez. Creep and Shrinkage of Nonproprietary Ultra-High Performance Concrete. Precast/Prestressed Concrete Institute, 2023. http://dx.doi.org/10.15554/pci.rr.mat-014.
Texte intégralRésumé :
Work to characterize the creep and shrinkage of UHPC has been mainly performed on proprietary or lab-formulated mixes; this report describes the first effort to characterize creep and shrinkage properties of UHPC mixes explicitly formulated for use in large-scale precast/prestressed operations. To provide better knowledge about UHPCs, the research group at The Ohio State University performed a comprehensive study on the creep and shrinkage behavior of five UHPC mixes developed for use in the precast/prestressed industry using non-proprietary, locally available materials. This report details the experimental effort and its findings.
2
Bernstein. L51921 Evaluating the Remaining Creep Life of Gas Turbine Blades. Pipeline Research Council International, Inc. (PRCI), 2001. http://dx.doi.org/10.55274/r0011270.
Texte intégralRésumé :
A study was performed on methods to determine the remaining creep life of gas turbine blades. The objective of the study was to develop a remaining creep life methodology that will allow greater life to be obtained from these very expensive engine components. The focus of this study was on methods of physical testing, especially mechanical testing.
3
Thembeka Ncube, Ayanda, and Antonio Bobet. Use of Recycled Asphalt. Purdue University, 2021. http://dx.doi.org/10.5703/1288284317316.
Texte intégralRésumé :
The term Reclaimed Asphalt Pavement (RAP) is used to designate a material obtained from the removal of pavement materials. RAP is used across the US in multiple applications, largely on asphalt pavement layers. RAP can be described as a uniform granular non-plastic material, with a very low percentage of fines. It is formed by aggregate coated with a thin layer of asphalt. It is often used mixed with other granular materials. The addition of RAP to aggregates decreases the maximum dry unit weight of the mixture and decreases the optimum water content. It also increases the Resilient Modulus of the blend but decreases permeability. RAP can be used safely, as it does not pose any environmental concerns. The most important disadvantage of RAP is that it displays significant creep. It seems that this is caused by the presence of the asphaltic layer coating the aggregate. Creep increases with pressure and with temperature and decreases with the degree of compaction. Creep can be mitigated by either blending RAP with aggregate or by stabilization with chemical compounds. Fly ash and cement have shown to decrease, albeit not eliminate, the amount of creep. Mechanical stabilizing agents such as geotextiles may also be used.
4
Wright, Jill K., Laura J. Carroll, and Richard N. Wright. Creep and Creep-Fatigue of Alloy 617 Weldments. Office of Scientific and Technical Information (OSTI), 2014. http://dx.doi.org/10.2172/1168621.
Texte intégral
5
Zaheen Nasir, K., Wen Jiang, and Benjamin Spencer. Creep and Creep Fracture Modeling with Surrogate Creep Models and the Extended Finite Element Method. Office of Scientific and Technical Information (OSTI), 2024. https://doi.org/10.2172/2480345.
Texte intégral
6
Dr. F. W. Brust, Dr. G. M. Wilkowski, Dr. P. Krishnaswamy, and Mr. Keith Wichman. Creep and Creep-Fatigue Crack Growth at Structural Discontinuities and Welds. Office of Scientific and Technical Information (OSTI), 2010. http://dx.doi.org/10.2172/974286.
Texte intégral
7
Ubic, Rick, Darryl Butt, and William Windes. Irradiation Creep in Graphite. Office of Scientific and Technical Information (OSTI), 2014. http://dx.doi.org/10.2172/1128528.
Texte intégral
8
JL Bump and RF Luther. Biaxial Creep Specimen Fabrication. Office of Scientific and Technical Information (OSTI), 2006. http://dx.doi.org/10.2172/884675.
Texte intégral
9
Frank E. Goodwin. Creep Resistant Zinc Alloy. Office of Scientific and Technical Information (OSTI), 2002. http://dx.doi.org/10.2172/809087.
Texte intégral
10
Kennedy, C. R. (Irradiation creep of graphite). Office of Scientific and Technical Information (OSTI), 1990. http://dx.doi.org/10.2172/6410826.
Texte intégral